SCHEMBL13589018

SCHEMBL13589018

Cc1ccc(C(ON=C2CCN(S(=O)(=O)c3cccc4c3ccn4C)CC2)c2ccc(F)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ ALDH1A1 P00352 5/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ SMN1; SMN2 Q16637 4/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ PKM P14618 2/20 0.33
▸ RHEB Q15382 1/20 0.32
▸ STAT1 P42224 1/20 0.31
▸ RORC P51449 1/20 0.31
▸ HTR6 P50406 1/20 0.31
▸ PKLR P30613 1/20 0.31
▸ GPR183 P32249 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4380325 0.96 L3MBTL1 (0.35) MEN1KMT2AALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL4377766 0.80 NR3C1 (0.40) MEN1KMT2AALDH1A1CYP1A2CYP2C19
SCHEMBL4377015 0.77 PKM (0.46) MEN1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL8218498 0.76 MGLL (0.40) KMT2AALDH1A1SMN1; SMN2LMNARHEB
SCHEMBL4378960 0.75 PKM (0.43) ALDH1A1PKMPKLR
SCHEMBL4380941 0.75 CHRM1 (0.39) MEN1KMT2AALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL4382795 0.74 THRB (0.43) MEN1KMT2AALDH1A1CYP1A2CYP2C19
SCHEMBL4381279 0.74 PKM (0.49) MEN1KMT2AALDH1A1L3MBTL1LMNA
SCHEMBL4385272 0.73 PKM (0.54) KMT2AALDH1A1SMN1; SMN2L3MBTL1LMNA
SCHEMBL4382549 0.73 TP53 (0.46) LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 MEN1 3694/4885KMT2A 2079/4885ALDH1A1 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback